Apr 11, 2013

Marketplace Morning Report for Thursday, April 11, 2013

Biogen Idec, a Massachusetts-based biotech company, is hoping its new multiple sclerosis drug Tecfidera will eventually bring in the hundreds of millions of dollars it cost to develop -- at least before a generic comes along and copies it. CEO George Scangos discusses his company's development process and pricing strategy. A new report from the research firm IDC says personal computer sales are falling fast all around the world. And in Phoenix, Arizona, new signs of a real estate bubble are emerging.

Segments From this episode

Biogen Idec CEO on drug costs and taking on multiple sclerosis

by Jeremy Hobson

Apr 11, 2013

Biogen Idec CEO George Scangos discusses his company's new multiple sclerosis drug, pricing strategy, and research process.

LISTEN

EMBED

BBC World Service

Global PC sales plunge, what's Microsoft got to do with it?

by Marketplace Contributor

Apr 11, 2013

Personal computer sales fell by 14 percent around the world during the first quarter of this year, according to a new report from the research firm IDC.

LISTEN

EMBED

Bidding wars, rising prices - but a housing bubble?

by Marketplace Contributor

Apr 11, 2013

Phoenix, Arizona, was hit hard during the housing crash. Now the housing market is recovering quickly and home buyers are frustrated. But one expert says that doesn't make a housing bubble.

LISTEN

EMBED

Farmers vs. cities in the war for water

by Adriene Hill

Apr 11, 2013

Water laws in the West often give priority to whose who used a water source first, often farmers. Farmers in New Mexico are fighting to regain their place at the head of the line.

LISTEN

EMBED

Gold prices sink as inflation stays at bay

by Marketplace Contributor

Apr 11, 2013

Diane Swonk, chief economist with Mesirow Financial, joins Marketplace Morning Report host Jeremy Hobson to discuss the drop off in gold prices and whether there is such a thing as a safe haven anymore.

LISTEN

EMBED

Mid-day Update

PODCAST: Water war, Biotech industry core

by Jeremy Hobson

Apr 11, 2013

Water wars heat up in New Mexico. CEO of Biogen Idec discusses high drug costs, a new drug for multiple sclerosis and what's up with pharmaceutical drug names.

LISTEN

EMBED

Biogen Idec, a Massachusetts-based biotech company, is hoping its new multiple sclerosis drug Tecfidera will eventually bring in the hundreds of millions of dollars it cost to develop — at least before a generic comes along and copies it. CEO George Scangos discusses his company’s development process and pricing strategy. A new report from the research firm IDC says personal computer sales are falling fast all around the world. And in Phoenix, Arizona, new signs of a real estate bubble are emerging.